Asset Details
Do you wish to reserve the book?
Imatinib mesylate in desmoplastic small round cell tumors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Imatinib mesylate in desmoplastic small round cell tumors
Do you wish to request the book?
Imatinib mesylate in desmoplastic small round cell tumors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Imatinib mesylate in desmoplastic small round cell tumors
2017
Overview
To investigate the possible role of imatinib, an inhibitor of the tyrosine kinase activity of PDGF-R, in desmoplastic small round cell tumor (DSRCT).
From August 2005 to June 2009, DSRCT patients refractory to conventional treatment were enrolled. Patients received imatinib 400 mg daily. Primary end point of this open label, prospective, Phase II trial was objective response rate.
Of the 13 enrolled patients, eight were evaluable for response. Median age was 20 years (range: 9-32). Objective responses at 3 months were: stable disease in one patient and progressive disease in seven patients.
Imatinib showed no efficacy in the treatment of DSRCT unresponsive to conventional therapy, despite molecular-based selection of patients.
Publisher
Future Medicine Ltd
Subject
/ Adult
/ c-KIT
/ Child
/ desmoplastic small round cell tumor
/ Desmoplastic Small Round Cell Tumor - drug therapy
/ Desmoplastic Small Round Cell Tumor - genetics
/ Desmoplastic Small Round Cell Tumor - pathology
/ Female
/ Gene Expression Regulation, Neoplastic - drug effects
/ Humans
/ imatinib
/ Imatinib Mesylate - administration & dosage
/ Imatinib Mesylate - adverse effects
/ Italy
/ Kinases
/ Male
/ Melanoma
/ Patients
/ PDGF-Rα
/ PDGF-Rβ
/ Proteins
/ Proto-Oncogene Proteins c-kit - antagonists & inhibitors
/ Proto-Oncogene Proteins c-kit - genetics
/ Receptor, Platelet-Derived Growth Factor alpha - antagonists & inhibitors
/ Receptor, Platelet-Derived Growth Factor alpha - genetics
/ Surgery
/ Tumors
